Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Common drug, given promptly, reduces incidence of post-traumatic stress disorder

24.10.2003


A common drug administered in the first hours following trauma to patients deemed to be at risk of developing post-traumatic stress disorder (PTSD) reduced the occurrence of PTSD, according to a study led by researchers at the University of Lille, France.


While the study involved a small number of subjects, its results are encouraging, says its senior author, Charles Marmar, MD, associate chief of staff for mental health at the San Francisco VA Medical Center and professor and vice chair of psychiatry at University of California, San Francisco.

"The study is based on the new theory that PTSD is most likely to occur in patients who experience a particularly severe and prolonged response to trauma. If this model proves accurate after five or ten replications of studies like this one, it could have very profound ramifications. From a public health perspective, if you could identify the subgroup of people who are susceptible to PTSD, giving them this course of medication -- which is brief, very well tolerated and inexpensive -- could be very effective prevention [following major trauma] and may have great social relevance." The study appears in the November 1 issue of Biological Psychiatry.

All people confronted by a life-threatening situation, such as a car accident or physical assault, react by releasing a rush of stress hormones, including adrenalin and noradrenalin, which are produced in the adrenal glands, located atop the kidneys. This response, known as "adrenergic activation," initiates the reactions that quicken the heart rate, constrict the vasculature to prevent bleeding to death, and provide energy to the muscles, priming the body to "fight, flee, or freeze." The hormonal flood also strengthens the brain’s ability to form and retain emotional memories. The longer the duration of the adrenergic activation, the more vivid and tenacious are the memories of the event. In most people, after minutes to hours the reaction begins to subside.



In some 25 percent of people, however, the hormonal response continues for hours, days, or even a week or longer. The working hypothesis of the new model is that these are the people who are at greatest risk for developing post-traumatic stress disorder, in which a person experiences recurring emotional attacks, for months, years or decades following the inciting event. PTSD patients experience such symptoms as insomnia, difficulty concentrating, persistent reliving of the traumatic event, and reactions of panic or fear when confronted with reminders of the event.

A diagnosis of PTSD is usually made when such symptoms persist at least four weeks following the trauma. For those who suffer from PTSD, memories can be so dogged and intense that they can be triggered years later by details of scenery, smells or sounds associated with the trauma. Some Vietnam veterans with PTSD, for example, feel more anxious on hot and humid days, because these conditions evoke their memories of jungle warfare.

The model now being explored by both basic and clinical researchers predicts that the more quickly a person calms down and regains a sense of safety and composure following trauma, the less vividly the event will be etched in memory, making him or her less likely to develop phobias of objects or actions related to the trauma, and such potent reminders of the trauma will be less likely to trigger panic and fear responses. Recent research involving accident victims in Australia and people exposed to the World Trade Center attacks support this hypothesis.

"Our working model is that if you experience a more intense panic reaction in a life-threatening situation and it takes you a longer period of time to calm down afterwards than most people, you are having a sustained adrenergic reaction and you are more likely to be among those 25 percent of people who are at risk of developing PTSD," Marmar says.

Thus, two important steps in early prevention of PTSD may be to identify the 25 percent of trauma victims who are at greatest risk of developing the disorder and to calm them as quickly as possible in order to block their adrenergic activity.

In the study, doctors in the emergency departments of two hospitals in France evaluated victims of physical assault or auto accidents for symptoms of prolonged panic reactions within two to twenty hours of the traumatic injury. Because one reliable indication of a sustained panic reaction is tachycardia, or elevated heart rate, the doctors chose patients for the study who were medically stable and had heart rates higher than 90 beats per minute measured after they had been lying down for 20 minutes. These patients were offered propranolol, a common drug also known by its brand name, Inderal, which is often prescribed for tachycardia, high blood pressure or anxiety. Those who accepted the drug were given an immediate dose of 40 mg and were then asked to take three daily doses of 40 mg for seven days, followed by a tapering off period of eight to twelve days.

When evaluated with a battery of psychological tests two months following the traumatic event, almost all patients exhibited some degree of symptoms associated with PTSD, but severity of symptoms was twice as high among patients who had not taken propranolol. Only one of 11 propranolol patients had symptoms severe enough to warrant a diagnosis of PTSD, while three of eight patients who declined the drug were diagnosed with the disorder.

Propranolol is one of a class of drugs known as beta-adrenergic antagonists that can control many of the physical symptoms of panic attacks, such as trembling, sweating, tachycardia and heart palpitations. The drug has also been shown to reduce memory for emotional events by blocking adrenergic pathways. For example, when either propranolol or a placebo were given to college students before they were shown disturbing films, the propranolol decreased the students’ anxiety both while they watched the film and weeks later when descriptions of the film were read to them.

Treatments for PTSD that have been shown to be beneficial are antidepressant medications and cognitive behavioral therapy -- a form of psychotherapy that works on changing a person’s patterns of thinking in order to curb unwanted thoughts and feelings. But the longer PTSD persists, the more difficult it is to treat. Without the benefit of skilled intervention, about a third of those people who have PTSD for a year or longer will suffer from it for many years or even decades. Moreover, many people do not recognize symptoms of the disorder, so they delay seeking treatments. Others are reluctant to ask for treatment for what may be perceived as an emotional disorder, and, in many places, specialized treatment resources are scarce. Given such problems in treating PTSD, many researchers are now looking for ways to prevent or reduce occurrence of the disorder.

Although not a randomized study, the propranolol and control groups did not differ significantly in characteristics such as age (all subjects were 21 to 30 years old), gender, employment, and marital status, degree of exposure, physical injury, or level of terror at the time of the assault or accident. All were medically screened, were free of cardiovascular complications from their exposure, and otherwise in good physical health. No one was enrolled in the study who had lost consciousness during the trauma, sustained serious brain injuries, had injuries compromising cardiovascular function, or who had a history of heart disease, asthma or PTSD.

This is the second study in which propranolol was promptly administered following traumatic injury. The first was conducted by Roger Pitman and colleagues at Harvard and published in 2002. In that investigation, 31 trauma victims who were evaluated in the first hours after traumatic exposure were randomly assigned to take propranolol or a placebo. Pitman’s team did not find fewer cases of PTSD in the propranalol group, but propranolol patients experienced lower measures of stress (lower heart rates and skin conductance measurements) than the placebo group when they listened to a vivid narrative of their traumatic event three months after its occurrence.

The first author of the study is Guillaume Vaiva, MD, PhD, at the Clinical School of Psychiatry, University of Lille Medical School, Lille, France. Co-authors are Drs. François Ducrocq, Karine Jezequel, Benoit Averland and Philippe Lestavel, all at University of Lille, and Dr. Alain Brunet, Department of Psychiatry, McGill University and the Douglas Hospital Research Center in Montreal, Canada.

Liese Greensfelder | EurekAlert!
Further information:
http://www.ucsf.edu

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

Decoding cement's shape promises greener concrete

08.12.2016 | Materials Sciences

Will Earth still exist 5 billion years from now?

08.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>